Bayer Links
Copyright ©
Bayer HealthCare AG
News archive
Bayer to Present Data on Late-Stage Development Oncology Compounds at ASCO 2012
First data from Phase III trial for regorafenib in gastrointestinal tumors (GIST) presented as Late-Breaking Abstract in Oral Abstract Session / Updated survival results from Phase III trial for Alpharadin (radium-223 chloride) in castration-resistant prostate cancer (CRPC) presented as Late-Breaking Abstract in Oral Abstract Session » more
"Lebenstagebuch" wins Aspirin Social Award 2012
Berlin institution offers traumatized children of the Second World War unique writing therapy / 2nd place: Ärzte-Netzwerk Berlin (network of physicians in Berlin): Medical care for homeless people / 3rd place: REBOUND: Heidelberg drug prevention program for school students / Bayer Board of Management member Dr. Pott at award ceremony at Humboldt University in Berlin: "Innovative social initiatives with valuable contributions to health care" » more
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA to Reduce the Risk of Stent Thrombosis in Patients with Acute Coronary Syndrome
Bayer’s cooperation partner, Janssen Research & Development, LLC has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration seeking approval for the use of Xarelto® (rivaroxaban) 2.5 mg BID to reduce the risk of stent thrombosis in patients with Acute Coronary Syndrome (ACS). » more
Bayer’s Xarelto® (Rivaroxaban) Submitted to U.S. FDA for the Treatment of Venous Thromboembolism (VTE) and Long-Term Prevention of Recurrent VTE
Submissions for marketing authorization supported by the successful global EINSTEIN study program / Rivaroxaban is the first oral single-drug solution proven effective for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) » more
Bayer has great potential for the future too
Fiscal 2011 was strategically and operationally successful / Proposal to raise the dividend for 2011 to EUR 1.65 per share / Encouraging start to 2012 / Good progress with the development of innovative products / Werner Wenning to become Chairman of the Supervisory Board on October 1 » more
Encouraging start to the year for Bayer
Sales increased by 6.8 percent to a record EUR 10,056 million / Operating result (EBIT) climbed by 42.6 percent to EUR 1,637 million / EBITDA before special items rose by 9.4 percent to EUR 2,442 million / Strong start to the season at CropScience – increases at HealthCare – continuing margin pressure at MaterialScience / Net income advanced by 53.5 percent to EUR 1,050 million / 2012 guidance confirmed » more
Positive results from two European Phase III trials with ATX-101 demonstrate reduction of submental fat
Bayer today announced the successful completion of two pivotal European Phase III clinical trials with ATX-101, an injectable drug for the reduction of unwanted fat under the chin. » more
Dr. Dirk Ehle appointed Head of Bayer HealthCare's Animal Health Division
Dr. Dirk Ehle has been appointed Head of the Animal Health Division of Bayer HealthCare AG effective May 1, 2012. The 42-year-old succeeds Dr. Jean-Luc Lowinski, who is leaving the company at his own request. » more
Bayer expands targeted cancer therapy collaboration with Amgen
Bayer HealthCare has agreed with Amgen Research (Munich) GmbH (formerly Micromet GmbH) to develop and commercialize another new Bispecific T cell Engager (BiTE®) antibody against an undisclosed target expressed in multiple tumors. » more
Real-World Experience Reaffirms Bayer’s Xarelto® (Rivaroxaban) as Safe and Effective in Protecting Patients Against Blood Clots
Outcomes from XAMOS study of more than 17,000 orthopaedic surgery patients provide further confirmation of clinical value of rivaroxaban / XAMOS reaffirms robust findings from RECORD – the world’s largest trial programme assessing oral anticoagulation in people requiring hip or knee replacement / Rivaroxaban is the world’s most prescribed new oral anticoagulant in the orthopaedic setting, with almost 2 million patients treated in this indication alone » more
Bayer sells PET tracers to Piramal
Bayer has entered into an agreement to sell its PET tracer assets envisioned to be used as in-vivo diagnostic agents, including its PET compound florbetaben, to Piramal Imaging SA. » more
Bayer HealthCare aims to improve diabetes management across borders
“Excellence across Borders” program initiated » more
New Seresto® keeps ticks and fleas at bay month after month
New collar from Bayer Animal Health offers dogs and cats an unparalleled protection period of up to eight months from ticks and fleas in a single treatment » more
Seresto® provides groundbreaking parasite protection in cats and dogs
New treatment from Bayer Animal Healthoffers cats and dogs up to eight months’ protection from ticks and fleas in a single treatment » more
Bayer’s Xarelto® (Rivaroxaban) Submitted for EU Marketing Authorisation for the Treatment of Pulmonary Embolism (PE) and Prevention of Recurrent Deep Vein Thrombosis (DVT) and PE
Submission based on the successful outcome of EINSTEIN-PE study / Rivaroxaban offers the first oral single-drug solution for the initial treatment of PE and long-term prevention of DVT and PE » more
Bayer Updates U.S. Labels for Drospirenone-containing Combined Oral Contraceptives
The U.S. Food and Drug Administration (FDA) and Bayer HealthCare Pharmaceuticals have agreed to update the labels for its drospirenone-containing combined oral contraceptives (COCs) in the United States. » more
Phase III Trial of Regorafenib in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Meets Primary Endpoint of Improving Progression-Free Survival
Bayer HealthCare today announced positive results from its Phase III trial GRID (GIST – Regorafenib In Progressive Disease) evaluating its investigational compound regorafenib (BAY 73-4506) for the treatment of patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease has progressed despite prior treatment with imatinib and sunitinib. » more
Bayer to Present New Data on Oncology Pipeline
New Preclinical Data Evaluating Innovative Compounds will be presented / Growing Research and Development Portfolio » more
Bayer HealthCare and Beijing’s Tsinghua University extend innovative drug discovery partnership
Bayer HealthCare Company Ltd and Tsinghua University in Beijing, China, are expanding their joint research partnership relating to the Bayer-Tsinghua Joint Research Center for Innovative Drug Discovery (BTC). This week, both partners signed a new strategic agreement to collaborate in the area of biomedical sciences over the next 3 years. » more
Bayer’s Xarelto® (Rivaroxaban) Proven Effective in Treating Patients with Pulmonary Embolism and in Preventing Recurrent Venous Blood Clots in Phase III EINSTEIN-PE Study
Rivaroxaban as effective as current standard of care in treatment of pulmonary embolism and secondary prevention of venous blood clots / Patients receiving rivaroxaban showed significantly reduced major bleedings compared to current standard of care / Rivaroxaban offers the first oral single-drug solution for the initial treatment and long-term prevention of pulmonary embolism / Study results presented as a Late-Breaker at the American College of Cardiology Annual Scientific Sessions and published in the New England Journal of Medicine » more
Results of the Phase III EINSTEIN-PE Study with Bayer’s Xarelto® (Rivaroxaban) to be Presented in Late-Breaking Clinical Trials Session at ACC 2012
Bayer HealthCare announced today that findings from the Phase III EINSTEIN-PE study, with almost 5,000 patients, will be presented in the Late-Breaking Clinical Trials Session on Monday, March 26th, 2012, 08:00 – 09:30am CDT, at the American College of Cardiology’s 61st Annual Scientific Sessions (ACC) in Chicago, USA, by lead investigator Harry R. Buller, MD, Academic Medical Center, Amsterdam, the Netherlands. » more
U.S. FDA approves Natazia™ as the first combined oral contraceptive to treat heavy menstrual bleeding (HMB)
The U.S. Food and Drug Administration (FDA) has approved a new indication for Natazia™ (estradiol valerate and dienogest) tablets for the treatment of heavy menstrual bleeding (HMB) that is not caused by any diagnosed conditions of the uterus (womb), in women who choose to use a combined oral contraceptive for contraception. » more
EYLEA® (aflibercept) Injection approved for the Treatment of Wet Age-Related Macular Degeneration in Australia
Approval based on positive results of VIEW 1 and VIEW 2 clinical trials » more
Bayer HealthCare integrates its Contrast Media, Injector and Interventional businesses
New business unit named “Radiology and Interventional” broadens customer offerings and speeds up innovations / Unit encompasses leading brands Gadovist®, Ultravist®, AngioJet Ultra®, Mark 7 Arterion™ Injection System and Stellant® D CT Injection System » more
Bayer: sales and EBIT at record levels
Sales increase by 4.1 percent to EUR 36,528 million / Operating result (EBIT) improves by 52.0 percent to EUR 4,149 million / EBITDA before special items advances by 7.2 percent to EUR 7,613 million / Growth at HealthCare and CropScience, decline in momentum at MaterialScience / Net income climbs by 89.9 percent to EUR 2,470 million / Success of new products creates optimism for the future / Presence in emerging markets further expanded / Forecast for 2012: slight increase in underlying earnings » more
Bayer Acquires Animal Health Business from KMG Chemicals
Acquisition will strengthen Bayer HealthCare’s Animal Health insecticides business » more
Bayer’s A1CNow+ as accurate as standard laboratory system
Useful solution for doctor’s offices and emergency labs » more
Contour XT exceeds ISO 15197:2003 accuracy criteria
New innovative technology system provides advanced monitoring accuracy » more
Search
Page tools
click to adjust font size
Social Bookmarks
Bayer HealthCare Links
Newsroom
